An Open-Label Study to Investigate the Total Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand 18F-JNJ-64326067 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2018
At a glance
- Drugs Fluorine-18-MNI-1020 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Janssen Research & Development
- 29 Nov 2018 Status changed from recruiting to completed.
- 24 Aug 2018 Planned primary completion date changed from 10 Aug 2018 to 21 Sep 2018.
- 31 Jul 2018 Planned End Date changed from 10 Aug 2018 to 21 Sep 2018.